A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Advanced Gastric Cancer
Interventions: BIOLOGICAL: MASCT-I|DRUG: PD1 antibody
Sponsor: HRYZ Biotech Co.
Collaborators: Peking University Cancer Hospital & Institute